Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Sumitomo Dainippon Pharma Co Ltd    4506   JP3495000006

SUMITOMO DAINIPPON PHARMA CO LTD (4506)
My previous session
Most popular
  Report  
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (JPY)
Sales 2019 463 B
EBIT 2019 -
Net income 2019 38 218 M
Finance 2019 131 B
Yield 2019 0,54%
Sales 2020 473 B
EBIT 2020 -
Net income 2020 42 400 M
Finance 2020 156 B
Yield 2020 0,53%
P/E ratio 2019 37,34
P/E ratio 2020 35,27
EV / Sales2019 2,91x
EV / Sales2020 2,79x
Capitalization 1 478 B
More Financials
Company
Dainippon Sumitomo Pharma Co. specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (90.8%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems... 
Sector
Pharmaceuticals
Calendar
01/31Earnings Release
More about the company
Surperformance© ratings of Sumitomo Dainippon Pharma
Trading Rating : Investor Rating :
More Ratings
Latest news on SUMITOMO DAINIPPON PHARMA
01/11SUMITOMO DAINIPPON PHARMA : Announces Positive Topline Results from a Phase III ..
AQ
2018FDA approves Acorda's Inbrija for Parkinson's
AQ
2018SUMITOMO DAINIPPON PHARMA : Announces Resolution of Consolidated Patent Infringe..
AQ
2018MANAGEMENT TRACKS : PolarityTE and Foamix hire first chief commercial officers
AQ
2018SUMITOMO DAINIPPON PHARMA : CMS takes aim at protected drug classes, allowing st..
AQ
2018ASIA MARKETS: Asian Markets Mixed Ahead Of U.S. Midterm Elections
DJ
2018SUMITOMO DAINIPPON PHARMA : Sumitomo Dainippon Pharma announces the Clinical Dat..
AQ
2018SUMITOMO DAINIPPON PHARMA CO LTD : Slide show half-year results
CO
2018SUMITOMO DAINIPPON PHARMA : to Invest in and Start Joint Research and Developmen..
AQ
2018Poxel Announces Third Quarter and Nine Months 2018 Financial Update
AQ
More news
Analyst Recommendations on SUMITOMO DAINIPPON PHARMA
More recommendations
Sector news : Pharmaceuticals - NEC
09:12aGLAXOSMITHKLINE : GSK completes acquisition of -2-
DJ
09:12aGLAXOSMITHKLINE : GSK completes acquisition of TESARO
DJ
08:51aJOHNSON & JOHNSON : 2019 revenue forecast misses expectations
RE
07:46aJOHNSON & JOHNSON : Litigation Costs Double in Fourth Quarter
DJ
03:54a'A List' climate change firms outperform on stock market - survey
RE
More sector news : Pharmaceuticals - NEC
Chart SUMITOMO DAINIPPON PHARMA CO LTD
Duration : Period :
Sumitomo Dainippon Pharma Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SUMITOMO DAINIPPON PHARMA
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 9
Average target price 2 600  JPY
Spread / Average Target -30%
EPS Revisions
Managers
NameTitle
Hiroshi Nomura President & Representative Director
Masayo Tada Chairman
Yoshiharu Ikeda General Manager-Research Technology
Nobuyuki Hara Director, Executive Officer & GM-Development
Hitoshi Odagiri Director, Managing Executive Officer & GM-Sales
Sector and Competitors
1st jan.Capitalization (M$)
SUMITOMO DAINIPPON PHARMA CO LTD12.52%13 506
JOHNSON & JOHNSON1.27%350 508
PFIZER-2.57%246 674
NOVARTIS5.09%227 840
ROCHE HOLDING LTD.5.96%223 053
MERCK AND COMPANY-0.71%197 291